BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 22519363)

  • 1. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
    Kolho KL; Valtonen E; Rintamäki H; Savilahti E
    Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
    Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
    Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated MMP-8 and decreased myeloperoxidase concentrations associate significantly with the risk for peripheral atherosclerosis disease and abdominal aortic aneurysm.
    Pradhan-Palikhe P; Vikatmaa P; Lajunen T; Palikhe A; Lepäntalo M; Tervahartiala T; Salo T; Saikku P; Leinonen M; Pussinen PJ; Sorsa T
    Scand J Immunol; 2010 Aug; 72(2):150-7. PubMed ID: 20618774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alterations of metalloproteinases and their inhibitors concentrations in peripheral blood in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass].
    Paśnik J; Cywińska-Bernas A; Moll J; Moll J; Sysa A; Zeman K
    Przegl Lek; 2009; 66(7):359-64. PubMed ID: 20043576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.